SE9603533L - Specifika peptider för behandling av diabetes mellitus - Google Patents

Specifika peptider för behandling av diabetes mellitus

Info

Publication number: SE9603533L
Authority: SE; Sweden
Prior art keywords: peptides; atpase activity; treatment; diabetes mellitus; specific peptides
Prior art date: 1996-09-27

Application number

SE9603533A

Other languages

Unknown language ( )

English (en)

Other versions

SE9603533D0 (sv

SE520392C2 (sv

Inventor

John Wahren

Bo-Lennart Johansson

Hans Joernvall

Original Assignee

Creative Peptides Sweden Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-27

Filing date

1996-09-27

Publication date

1998-03-28

1996-09-27 Application filed by Creative Peptides Sweden Ab filed Critical Creative Peptides Sweden Ab

1996-09-27 Priority to SE9603533A priority Critical patent/SE520392C2/sv

1996-09-27 Publication of SE9603533D0 publication Critical patent/SE9603533D0/sv

1997-09-26 Priority to JP10515410A priority patent/JP2001500893A/ja

1997-09-26 Priority to ES97942119T priority patent/ES2278394T3/es

1997-09-26 Priority to HU0000432A priority patent/HUP0000432A3/hu

1997-09-26 Priority to CZ991085A priority patent/CZ108599A3/cs

1997-09-26 Priority to AU43915/97A priority patent/AU741901B2/en

1997-09-26 Priority to PL97332494A priority patent/PL332494A1/xx

1997-09-26 Priority to TR1999/00694T priority patent/TR199900694T2/xx

1997-09-26 Priority to DE69737065T priority patent/DE69737065T2/de

1997-09-26 Priority to US09/269,439 priority patent/US6610649B2/en

1997-09-26 Priority to KR1019990702585A priority patent/KR20000048643A/ko

1997-09-26 Priority to IL12914397A priority patent/IL129143A0/xx

1997-09-26 Priority to SK394-99A priority patent/SK39499A3/sk

1997-09-26 Priority to RU99108434/14A priority patent/RU2206336C2/ru

1997-09-26 Priority to BR9711573-8A priority patent/BR9711573A/pt

1997-09-26 Priority to NZ335231A priority patent/NZ335231A/xx

1997-09-26 Priority to PCT/GB1997/002627 priority patent/WO1998013384A1/en

1997-09-26 Priority to AT97942119T priority patent/ATE347562T1/de

1997-09-26 Priority to DK97942119T priority patent/DK0938503T3/da

1997-09-26 Priority to CA002266416A priority patent/CA2266416C/en

1997-09-26 Priority to EP97942119A priority patent/EP0938503B1/en

1998-03-28 Publication of SE9603533L publication Critical patent/SE9603533L/sv

1999-03-23 Priority to IS5008A priority patent/IS5008A/is

1999-03-26 Priority to NO991483A priority patent/NO991483L/no

1999-04-27 Priority to BG103362A priority patent/BG103362A/xx

2003-07-01 Publication of SE520392C2 publication Critical patent/SE520392C2/sv

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
206010012601 diabetes mellitus Diseases 0.000 title 1
108091006112 ATPases Proteins 0.000 abstract 3
102000057290 Adenosine Triphosphatases Human genes 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
239000012634 fragment Substances 0.000 abstract 3
208000002249 Diabetes Complications Diseases 0.000 abstract 2
108010075254 C-Peptide Proteins 0.000 abstract 1
206010012655 Diabetic complications Diseases 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000003592 biomimetic effect Effects 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
210000002950 fibroblast Anatomy 0.000 abstract 1
108010038088 glutamyl-glycyl-seryl-leucyl-glutamine Proteins 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
150000002894 organic compounds Chemical class 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
210000005233 tubule cell Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

SE9603533A 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus SE520392C2 (sv)

Priority Applications (24)

Application Number	Priority Date	Filing Date	Title
SE9603533A SE520392C2 (sv)	1996-09-27	1996-09-27	Specifika peptider för behandling av diabetes mellitus
EP97942119A EP0938503B1 (en)	1996-09-27	1997-09-26	Insulin c-peptides
SK394-99A SK39499A3 (en)	1996-09-27	1997-09-26	Peptide, biomimetic organic compound thereof, pharmaceutical composition containing it and its use
BR9711573-8A BR9711573A (pt)	1996-09-27	1997-09-26	Pepetìdeos c da insulina.
HU0000432A HUP0000432A3 (en)	1996-09-27	1997-09-26	Insulin c-peptides
CZ991085A CZ108599A3 (cs)	1996-09-27	1997-09-26	Peptid, který je fragmentem C-peptidu lidského inzulinu
AU43915/97A AU741901B2 (en)	1996-09-27	1997-09-26	Insulin C-peptides
PL97332494A PL332494A1 (en)	1996-09-27	1997-09-26	Peptides of c insulin
TR1999/00694T TR199900694T2 (xx)	1996-09-27	1997-09-26	�nsulin C-peptitleri.
DE69737065T DE69737065T2 (de)	1996-09-27	1997-09-26	Insulin c-peptide
US09/269,439 US6610649B2 (en)	1996-09-27	1997-09-26	Insulin C-peptides
KR1019990702585A KR20000048643A (ko)	1996-09-27	1997-09-26	인슐린 ｃ-펩티드
IL12914397A IL129143A0 (en)	1996-09-27	1997-09-26	Insulin c-peptides
JP10515410A JP2001500893A (ja)	1996-09-27	1997-09-26	インスリンｃ―ペプチド
RU99108434/14A RU2206336C2 (ru)	1996-09-27	1997-09-26	Фрагмент с-пептида человеческого проинсулина
ES97942119T ES2278394T3 (es)	1996-09-27	1997-09-26	Peptidos c de la insulina.
NZ335231A NZ335231A (en)	1996-09-27	1997-09-26	Human fragments of insulin C-peptides of the sequence ELGGGPGAG or EGSLQ that have Na/K ATPase stimulating activity
PCT/GB1997/002627 WO1998013384A1 (en)	1996-09-27	1997-09-26	Insulin c-peptides
AT97942119T ATE347562T1 (de)	1996-09-27	1997-09-26	Insulin c-peptide
DK97942119T DK0938503T3 (da)	1996-09-27	1997-09-26	Insulin C-peptider
CA002266416A CA2266416C (en)	1996-09-27	1997-09-26	Insulin c-peptides
IS5008A IS5008A (is)	1996-09-27	1999-03-23	C-peptíð insúlíns
NO991483A NO991483L (no)	1996-09-27	1999-03-26	Insulin C-peptider
BG103362A BG103362A (en)	1996-09-27	1999-04-27	Insulin c-peptides

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9603533A SE520392C2 (sv)	1996-09-27	1996-09-27	Specifika peptider för behandling av diabetes mellitus

Publications (3)

Publication Number	Publication Date
SE9603533D0 SE9603533D0 (sv)	1996-09-27
SE9603533L true SE9603533L (sv)	1998-03-28
SE520392C2 SE520392C2 (sv)	2003-07-01

Family

ID=20404052

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9603533A SE520392C2 (sv)	1996-09-27	1996-09-27	Specifika peptider för behandling av diabetes mellitus

Country Status (24)

Country	Link
US (1)	US6610649B2 (sv)
EP (1)	EP0938503B1 (sv)
JP (1)	JP2001500893A (sv)
KR (1)	KR20000048643A (sv)
AT (1)	ATE347562T1 (sv)
AU (1)	AU741901B2 (sv)
BG (1)	BG103362A (sv)
BR (1)	BR9711573A (sv)
CA (1)	CA2266416C (sv)
CZ (1)	CZ108599A3 (sv)
DE (1)	DE69737065T2 (sv)
DK (1)	DK0938503T3 (sv)
ES (1)	ES2278394T3 (sv)
HU (1)	HUP0000432A3 (sv)
IL (1)	IL129143A0 (sv)
IS (1)	IS5008A (sv)
NO (1)	NO991483L (sv)
NZ (1)	NZ335231A (sv)
PL (1)	PL332494A1 (sv)
RU (1)	RU2206336C2 (sv)
SE (1)	SE520392C2 (sv)
SK (1)	SK39499A3 (sv)
TR (1)	TR199900694T2 (sv)
WO (1)	WO1998013384A1 (sv)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0022342D0 (en) *	2000-09-12	2000-10-25	Creative Peptides Sweden Ab	Reduction of the electrocardiographic QT interval
DE10055857A1 (de) *	2000-11-10	2002-08-22	Creative Peptides Sweden Ab Dj	Neue pharmazeutische Depotformulierung
US20030198666A1 (en) *	2002-01-07	2003-10-23	Richat Abbas	Oral insulin therapy
CA2511530C (en) *	2003-01-06	2013-07-09	Emisphere Technologies, Inc.	Night-time oral insulin therapy
US20050026826A1 (en) *	2003-01-17	2005-02-03	Margarethe Hoenig	Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en) *	2004-03-05	2005-09-15	Emisphere Technologies, Inc.	Oral insulin therapies and protocol
GB0323979D0 (en)	2003-10-13	2003-11-19	Creative Peptides Sweden Ab	Therapeutic applications for c-peptide
US7557081B2 (en) *	2004-05-27	2009-07-07	Essential Skincare, Llc	Alpha-1-acid glycoprotein for the treatment of diabetes
US7833513B2 (en)	2004-12-03	2010-11-16	Rhode Island Hospital	Treatment of Alzheimer's Disease
GB0601950D0 (en) *	2006-01-31	2006-03-15	Creative Peptides Sweden Ab	Compositions and methods of treating diabetes
JP5256199B2 (ja) *	2006-08-07	2013-08-07	テヴァバイオファーマシューティカルズユーエスエー，インコーポレーティッド	アルブミン−インスリン融合タンパク質
KR20100057640A (ko) *	2007-09-11	2010-05-31	몬도바이오테크 래보래토리즈 아게	치료제로서의 인슐린 ｃ-펩티드 단독 또는 ｇｌｐ-1과의 배합물의 용도
GB0723250D0 (en) *	2007-11-28	2008-01-09	Univ Leeds	Compositions and methods for reducing macrovascular complications in diabetic patients
EP2341942A1 (en)	2008-09-19	2011-07-13	Nektar Therapeutics	Polymer conjugates of therapeutic peptides
US20110165112A1 (en) *	2008-09-19	2011-07-07	Nektar Therapeutics	Polymer conjugates of c-peptides
US8410049B2 (en) *	2009-10-28	2013-04-02	Cebix	Methods and kits for preventing hypoglycemia
CA2798518A1 (en)	2010-05-17	2011-11-24	Cebix, Inc.	Pegylated c-peptide
ES2673672T3 (es)	2011-02-11	2018-06-25	The Regents Of The University Of Michigan	Composiciones tripeptídicas y su uso para el tratamiento de la diabetes
US8962553B2 (en)	2011-11-17	2015-02-24	Cebix Ab	Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
RU2522897C1 (ru) *	2013-04-16	2014-07-20	Закрытое акционерное общество "ФАРМ-ХОЛДИНГ"	Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) *	2014-12-30	2016-11-16	건국대학교 산학협력단	프로인슐린의 면역학적 용도
CN104888201B (zh) *	2015-06-29	2018-04-27	齐锦生	用于防治糖尿病及其慢性并发症的肽类药物
WO2018141970A1 (en)	2017-02-06	2018-08-09	Resiliun B.V.	Interaction between c-peptides and elastin receptor, a model for understanding vascular disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU166913B (sv) *	1972-05-15	1975-06-28
JPS5210872B2 (sv)	1973-07-14	1977-03-26
JPS55105653A (en) *	1978-10-02	1980-08-13	Shionogi & Co Ltd	Tyrosyl c-peptides
CH650679A5 (de)	1981-08-27	1985-08-15	Lilly Co Eli	Gegen diabetes mellitus wirksames pharmazeutisches mittel.
US4652548A (en) *	1981-08-27	1987-03-24	Eli Lilly And Company	Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
DE3326473A1 (de)	1983-07-22	1985-01-31	Hoechst Ag, 6230 Frankfurt	Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en) *	1984-06-14	1986-04-08	Eli Lilly And Company	Anti-diabetic compounds
US5104854A (en)	1989-02-01	1992-04-14	Washington University	Antiviral peptides
PT93057B (pt)	1989-02-09	1995-12-29	Lilly Co Eli	Processo para a preparacao de analogos da insulina
US5364757A (en)	1990-05-21	1994-11-15	Administrators Of The Tulane Educational Fund	Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) *	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja)	1992-03-27	1993-10-19	Hoechst Japan Ltd	骨形成作用を有する新規な蛋白質およびその製造法
ES2142867T3 (es)	1992-04-13	2000-05-01	Oklahoma Med Res Found	Procedimientos y reactivos para el diagnostico de autoanticuerpos.
WO1994025071A1 (en)	1993-05-05	1994-11-10	Keith Rose	Polyoxime compounds and their preparation
AT400723B (de)	1993-08-27	1996-03-25	Biomay Prod & Handel	Rekombinante alternaria alternata allergene
DE69508605T2 (de)	1994-07-08	1999-07-22	Trustees Of Dartmouth College, Hanover, N.H.	Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
US6309853B1 (en) *	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9422175D0 (en)	1994-11-03	1994-12-21	Univ Dundee	Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en)	1995-05-05	1995-06-28	Smithkline Beecham Plc	Novel compounds
NZ331866A (en)	1996-03-15	2000-05-26	Corixa Corp	Compounds for immunotherapy and immunodiagnosis of prostate cancer
US6150500A (en)	1996-07-12	2000-11-21	Salerno; John C.	Activators of endothelial nitric oxide synthase

1996
- 1996-09-27 SE SE9603533A patent/SE520392C2/sv not_active IP Right Cessation
1997
- 1997-09-26 TR TR1999/00694T patent/TR199900694T2/xx unknown
- 1997-09-26 AU AU43915/97A patent/AU741901B2/en not_active Ceased
- 1997-09-26 ES ES97942119T patent/ES2278394T3/es not_active Expired - Lifetime
- 1997-09-26 EP EP97942119A patent/EP0938503B1/en not_active Expired - Lifetime
- 1997-09-26 WO PCT/GB1997/002627 patent/WO1998013384A1/en not_active Ceased
- 1997-09-26 SK SK394-99A patent/SK39499A3/sk unknown
- 1997-09-26 PL PL97332494A patent/PL332494A1/xx unknown
- 1997-09-26 CZ CZ991085A patent/CZ108599A3/cs unknown
- 1997-09-26 JP JP10515410A patent/JP2001500893A/ja not_active Ceased
- 1997-09-26 HU HU0000432A patent/HUP0000432A3/hu unknown
- 1997-09-26 AT AT97942119T patent/ATE347562T1/de not_active IP Right Cessation
- 1997-09-26 DE DE69737065T patent/DE69737065T2/de not_active Expired - Lifetime
- 1997-09-26 NZ NZ335231A patent/NZ335231A/xx unknown
- 1997-09-26 RU RU99108434/14A patent/RU2206336C2/ru not_active IP Right Cessation
- 1997-09-26 KR KR1019990702585A patent/KR20000048643A/ko not_active Withdrawn
- 1997-09-26 DK DK97942119T patent/DK0938503T3/da active
- 1997-09-26 CA CA002266416A patent/CA2266416C/en not_active Expired - Fee Related
- 1997-09-26 BR BR9711573-8A patent/BR9711573A/pt not_active Application Discontinuation
- 1997-09-26 US US09/269,439 patent/US6610649B2/en not_active Expired - Fee Related
- 1997-09-26 IL IL12914397A patent/IL129143A0/xx unknown
1999
- 1999-03-23 IS IS5008A patent/IS5008A/is unknown
- 1999-03-26 NO NO991483A patent/NO991483L/no not_active Application Discontinuation
- 1999-04-27 BG BG103362A patent/BG103362A/xx unknown

Also Published As

Publication number	Publication date
DK0938503T3 (da)	2007-04-10
DE69737065T2 (de)	2007-06-28
TR199900694T2 (xx)	1999-06-21
EP0938503B1 (en)	2006-12-06
CA2266416C (en)	2008-04-29
DE69737065D1 (en)	2007-01-18
EP0938503A1 (en)	1999-09-01
RU2206336C2 (ru)	2003-06-20
HUP0000432A2 (hu)	2000-08-28
NO991483L (no)	1999-05-18
ES2278394T3 (es)	2007-08-01
KR20000048643A (ko)	2000-07-25
IS5008A (is)	1999-03-23
BG103362A (en)	2000-05-31
SE9603533D0 (sv)	1996-09-27
CA2266416A1 (en)	1998-04-02
PL332494A1 (en)	1999-09-13
NO991483D0 (no)	1999-03-26
HUP0000432A3 (en)	2000-10-30
IL129143A0 (en)	2000-02-17
SK39499A3 (en)	1999-10-08
AU4391597A (en)	1998-04-17
SE520392C2 (sv)	2003-07-01
NZ335231A (en)	2000-11-24
WO1998013384A1 (en)	1998-04-02
US20020107175A1 (en)	2002-08-08
AU741901B2 (en)	2001-12-13
ATE347562T1 (de)	2006-12-15
US6610649B2 (en)	2003-08-26
JP2001500893A (ja)	2001-01-23
BR9711573A (pt)	2000-01-18
CZ108599A3 (cs)	1999-08-11

Legal Events

Date	Code	Title	Description
2008-05-20	NUG	Patent has lapsed

Publication	Publication Date	Title
SE9603533L (sv)	1998-03-28	Specifika peptider för behandling av diabetes mellitus
DE69531889D1 (de)	2003-11-13	Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
DE69739662D1 (de)	2009-12-31	Methode zur behandlung von wundheilung in diabetikern
ATE273996T1 (de)	2004-09-15	Zusammensetzung zur therapie von diabetes mellitus und fettsucht
PT1171465E (pt)	2004-12-31	Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
DE69710095D1 (de)	2002-03-14	Pharmazeutische zubereitung zur behandlung von diabetes
EA200100289A1 (ru)	2001-10-22	Способ введения инсулинотропных пептидов
ATE186219T1 (de)	1999-11-15	Kombination von antihormonale und bindende moleküle zur krebsbehandlung
ES2106721T3 (es)	1997-11-16	Uso de amilina o cgrp para el tratamiento de la diabetes mellitus.
ATE304371T1 (de)	2005-09-15	Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
WO1999064598A3 (de)	2000-03-16	Neue insulinanaloga mit erhöhter zinkbindung
ES2059457T3 (es)	1994-11-16	Utilizacion de bezafibrato para el tratamiento de la diabetes.
DE50009838D1 (de)	2005-04-28	Humanes antibiotisches protein
NO933742L (no)	1993-10-18	Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
PT869785E (pt)	2002-12-31	4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
PT1007085E (pt)	2002-05-31	Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
BR8904924A (pt)	1990-05-08	Composicao de tratamento de couro,sua utilizacao,processo para tratamento de couros,bem como couro assim tratado
DK1340507T3 (da)	2005-02-28	Anvendelse af et fibroblastvækstfaktor-bindingsprotein til behandling og diagnosticering af diabetiske sårhelingsforstyrrelser
DE69801907D1 (de)	2001-11-08	Verwendung von 9,10-secocholesta-5,7,10(19)-trien-1,3-ol (alfacalcidol)
BR9703451A (pt)	1998-12-22	Composto natural para tratamento de diabete câncer e etc